

GT Biopharma appoints David Cardino as VP, Finance

24 August 2018 | News

David Cardino is a financial and operational leader with over 15 years of experience in the pharmaceutical and biotech industries



GT Biopharma Inc. (GTBP) an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary platforms, has announced the appointment of David Cardino, CPA, MBA as Vice President of Finance effective August 20, 2018.

David Cardino is a financial and operational leader with over 15 years of experience in the pharmaceutical and biotech industries. Most recently, he led the finance and accounting operations of Agensys, Inc., a U.S. based oncology research center of Astellas Pharma, Inc., with a pipeline of naked and antibody-drug-conjugated (ADC) therapeutic antibodies directed at a variety of cancer indications, with annual expenses and capital investment in excess of \$100M.

Prior to joining Agensys, Mr. Cardino held positions of increasing responsibility at MannKind Corporation, providing strategic and financial support to the R&D and commercial organizations, and serving on the finance and pharmaceutical development leadership teams.

Previous to MannKind, David held various positions at Merck & Co., Inc in areas including pharmaceutical economics, R&D portfolio evaluation, insurance and risk management, and manufacturing financial services. David began his career as an auditor with Price Waterhouse LLP. He is a certified public accountant in the state of New Jersey and holds a B.A. degree in Economics-Accounting from the College of the Holy Cross, and an M.B.A. from Duke University's Fuqua School of Business.